Prostate cancer (PC) care is rapidly evolving, with improved treatment options and outcomes. Trials recently published in the New England Journal of Medicine report on an oral lutenizing-hormone-releasing hormone antagonist with superior endocrine and tolerability profiles and positive outcomes for non-metastatic PC with androgen receptor antagonists, respectively.
Cancer cell. 2020 Jul 13 [Epub]
Alec Paschalis, Johann S de Bono
The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK., The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: .